Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Emcure Pharmaceuticals Limited

NSE: EMCUREPharmaceuticals

Share price

₹1,851.50

-3.47% close of 8 Oct 2026

Market cap ₹35,179 CrP/E 34.2

Business score

How strong the business is, in one number. The parts behind it are in Pro.

75

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹35,179 Cr

P/E ratio

34.2

P/B ratio

7.1

ROCE

24.0%

ROE

20.1%

Dividend yield

0.2%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹2,009.6052-week low ₹1,318.90

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales grew 18.4% over the past year, and 17.7% a year over its longer record. Meanwhile what it keeps of every 100 rupees of sales improved from 18.4% to 20.5% over the last two years.

Whether it grew faster than its sector

It grew 17.7% a year against a sector median of 13.1% — 4.7 percentage points faster.

Room to re-rate, or risk of de-rating

Too little price history yet to compare it with its own past.

Whether growth justifies the valuation

Priced at 1.6 times its growth rate, on earnings growth of 21%.

Profit growthPrice per ₹1 profitPer 1% growth
Emcure Pharmaceuticals Limited — this one21%/yr34.2×₹1.6
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 28 of 130 on returns, 28 of 127 on growth, 66 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A wide advantage: it earns 24% on capital, ahead of 78% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹4408 crore of cash from the business, spent ₹2037 crore on plant and equipment, and returned ₹932 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 8 years, about 145 arrived as cash (before interest, which is why it can exceed the profit). Its cash comes back more slowly than it used to: it went from being waiting 9 days for its cash to waiting 62 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

8 of 9 checks clear · 89%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Revenue grew 22.8% as management kept FY27 sales growth near the high end of its low-to-mid-teen guide.

Announced 6 Aug 2026 · Consolidated · Unaudited

Revenue

₹2,580 Cr

Revenue vs last year

+22.8%

Revenue vs last quarter

+4.5%

Net profit

₹292 Cr

Profit vs last year

+36.0%

Profit vs last quarter

+19.9%

Net margin

11.3%

EPS

₹15.50

Earnings call transcript · 6 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹35,179 Cr
Prev close
₹1,851.50
52w High
₹2,101
52w Low
₹1,307
Enterprise value
₹36,497 Cr
Beta
0.8
Price CAGR 1y
39.0%
Price CAGR 3y
—
Price CAGR 5y
—
Price CAGR 10y
—

Ratios

Return on assets
9.9%
PEG ratio
1.6
P/E ratio
34.2
P/B ratio
7.1
EV / EBITDA
21.0
Industry P/E
38.0
ROCE
24.0%
ROCE 5y average
22.0%
ROE
20.1%
Debt / Equity
0.3
Interest coverage
9.9
Dividend yield
0.2%
ROE 3y average
19.0%
ROE last year
20.0%

Annual P&L

Annual revenue
₹9,204 Cr
Annual profit
₹941 Cr
Operating margin
19.0%
Net profit margin
10.2%
EBITDA margin
19.0%
Sales growth 3y
15.4%
Sales growth 5y
12.8%
Profit growth 3y
21.0%
Profit growth 5y
18.0%
EPS
₹48.8
Sales growth TTM
18.0%
Profit growth TTM
37.0%
Dividend payout
7.0%

Quarter P&L

Sales latest quarter
₹2,580 Cr
Profit latest quarter
₹292 Cr
YoY quarterly sales growth
22.8%
YoY quarterly profit growth
35.8%
OPM latest quarter
20.6%

Balance Sheet

Book Value
₹261
Face Value
₹10.0
Total debt
₹1,521 Cr
Total cash
₹148 Cr
Borrowings
₹1,521 Cr
Reserves / Equity
25.1

Cash Flow

Operating cash flow
₹944 Cr
Free cash flow
₹400 Cr
FCF yield
0.7%
Net cash flow
₹112 Cr

Shareholding

Promoter holding
77.8%
FII holding
4.9%
DII holding
8.5%
Public holding
8.8%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,781.0033.84,27,3220.902,901.26.015,299.910.520.5
Divi's Lab.9,588.0085.42,54,5310.31902.065.53,080.027.822.0
Torrent Pharma.4,716.2080.41,79,3890.81566.05.84,921.054.915.2
Zydus Lifesci.1,153.0023.61,15,0120.09990.2-35.18,017.022.021.1
Laurus Labs2,052.80101.41,10,9150.10362.1125.52,026.329.117.8
Cipla1,327.2030.01,07,2210.98785.6-39.27,119.32.315.5
Mankind Pharma2,500.0048.41,03,2610.04574.129.64,030.612.913.5
Emcure Pharma1,918.0035.336,3870.19292.540.52,580.522.924.0
Median417.9034.52,2080.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales1,5561,6631,6681,7711,8152,0021,9632,1162,1012,2702,3632,4702,580
Expenses1,2611,3341,3741,4601,4791,6211,6081,7141,6841,7941,8711,9902,048
Material Cost404433420421419481
Change in Inventories-84-181-156-19-7737
Purchases of Stock-in-Trade572550625560661555
Employee Cost373393385387387409
Other Expenses448488520521600565
Operating Profit296329294311336381355402417475493480532
OPM %19201818191918192021211921
Other Income15-2221223364-603-36142
Exceptional items (within Other Income)-10-3.500-38100
Interest52596165594632392733384632
Depreciation677084919497979799105105106110
Profit before tax191198171167207273230261291341314341394
Tax %26263027262632242626262926
Net Profit141146120121153202156197215251231244292
EPS in Rs7.217.696.276.367.95108.119.971113121316
Diluted EPS in Rs9.971113121316

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales4,7175,0495,0335,8555,9866,6587,8969,2049,683
Expenses3,9684,3403,8174,5254,8045,4296,4277,4587,703
Material Cost1,5271,693
Change in Inventories-264-433
Purchases of Stock-in-Trade1,8832,397
Employee Cost1,4461,552
Other Expenses1,8292,130
Operating Profit7497081,2161,3301,1821,2301,4691,7461,980
OPM %161424232018191920
Other Income72-25-15963394762100-17
Exceptional items (within Other Income)-10-31
Interest223257155176214237176144148
Depreciation267321250245260312384415425
Profit before tax3311056529737477279711,2871,390
Tax %374362825272727
Net Profit2091014197035625287079411,019
EPS in Rs114.6223372928364953
Diluted EPS in Rs3649
Dividend Payout %3254487787

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
—
5 years
13%
3 years
15%
TTM
18%

Compounded profit growth

10 years
—
5 years
18%
3 years
21%
TTM
37%

Stock price CAGR

10 years
—
5 years
—
3 years
—
1 year
39%

Return on equity

10 years
—
5 years
21%
3 years
19%
Last year
20%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital181181181181181181189190
Reserves1,6541,7312,0921,8072,3202,7714,2574,760
Borrowings2,1282,3272,3102,2172,3342,3351,0231,521
Other Liabilities1,6131,7212,1841,8161,7982,4222,6533,043
Minority Interest19527
Total Liabilities5,5775,9606,7686,0216,6347,7098,1229,514
Fixed Assets2,2472,3822,1882,0442,1473,1253,1973,319
CWIP581485302320411159177273
Investments00025253189520
Other Assets2,7493,0934,2783,6324,0504,1084,6525,903
Total Assets5,5775,9606,7686,0216,6347,7098,1229,514

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity4445007047687471,097852944
Cash from Investing Activity-409-168-256-574-468-715-96-1,175
Cash from Financing Activity-735-301-189-152-145-164-814343
Net Cash Flow-7003225942134219-58112
Free Cash Flow39362571349345801476401

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days75831078210110293102
Inventory Days234211293237223225224239
Days Payable142133188184175193172180
Cash Conversion Cycle167161212135148134145161
Working Capital Days-15-28-16922287662
ROCE %11222621192024

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters7878787878787878
FIIs2.913.053.062.863.293.593.354.87
DIIs3.963.873.442.844.366.106.108.46
Public151516161412138.84
No. of Shareholders1,52,9141,43,4491,39,6711,33,5491,26,1691,18,8631,22,1891,24,991

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +32.6% (₹1,395.80 → ₹1,851.50)Brick size ₹57.39 (fixed)Bricks 16
₹1,400₹1,600₹1,852Jan '26Jul '26
Price moved up one brickPrice moved down one brickLast close ₹1,851.50 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

R&D as % of revenue

3.50pct

2026-06-30

FY revenue / permanent employees + workers, same basis (calc)

75,83,437inr

2026-03-31

News

News and filings about Emcure Pharmaceuticals Limited. Open one to see why it matters.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • Active Pharmaceutical Ingredients (APIs)
  • Excipients
  • Key starting materials and intermediates
  • Packaging materials
  • Solvents

Sells to

  • Gilead / Bristol-Myers Squibb ARV global-access programs
  • Roche

Buys from

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE168P01015

Plants

  • Bhosari Solid Orals Facility
  • Gandhinagar R&D Center
  • Hinjawadi Biotech Facility
  • Hinjawadi Oncology Injectable Facility
  • Hinjawadi Small Volume Parenteral Facility
  • Hinjawadi Solid Dosage Facility
  • Jammu Solid Orals Facility
  • Kurkumbh API Facility
  • Sanand Injectables Facility

News impact

Big market events that reach Emcure Pharmaceuticals Limited, and how the effect spreads.

Who it hits first

  • Bain Capital sells its entire Emcure Pharmaceuticals stake, creating a near-term equity supply overhang

Who may gain

  • No direct corporate beneficiary - this is a financial-investor exit; long-term, removal of the PE overhang can benefit Emcure once the block is absorbed

Along the supply chain

Downstream

No downstream disruption - drug supply to distributors/hospitals continues unchanged

Upstream

No supply-chain impact - API/raw-material sourcing for Emcure is unaffected by the ownership change

Where demand moves

Business

No business demand transfer - Emcure's drug pipeline, customers and operations are unchanged by a shareholding change

Capital

Near-term capital outflow as Bain's block is placed with new institutional buyers; absorption depends on appetite for a strong (ROE 20%) mid-cap pharma name

How it spreads across sectors

Healthcare

Idiosyncratic to Emcure; peers are not fundamentally affected by a financial sponsor's exit, though it tests institutional appetite for pharma blocks

When it plays out

Immediate

Block-driven price overhang on Emcure

Medium term

With PE overhang removed and fundamentals strong, scope for re-rating once the supply is digested

Short term

Absorption of the placed stock by new holders; volatility around the block clearing

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

4 Sep 2026unspecified₹3.6
14 Aug 2025unspecified₹3

Splits, bonuses & buybacks

  • daily-prices repair: 1 rows from NSE's archive (replace 0, delete 0, insert 1), 2026-02-01..2026-02-01 (docs/flat_day_repair.md)1× · 1 Feb 2026

Bulk & block deals

DateWhoBought / soldSharesPrice
25 Jun 2026BC INVESTMENTS IV LIMITEDSELL9,69,730₹1,817.00
25 Jun 2026BC INVESTMENTS IV LIMITEDSELL9,69,729₹1,817.00
9 Jun 2026KOTAK MAHINDRA MUTUAL FUNDBUY36,00,000₹1,700.00
9 Jun 2026BC INVESTMENTS IV LIMITEDSELL36,00,000₹1,700.00
29 Apr 2026NORGES BANK ON ACCOUNT OF THE GOVERNMENT PENSION FUND GLOBALBUY18,00,000₹1,608.20
29 Apr 2026BC INVESTMENTS IV LIMITEDSELL18,00,000₹1,608.20

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.